Get started
Work

Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF

Year: 2020
Type: article
DOI: 10.1016/j.jchf.2020.08.014
Authors: Karola S. Jering, Faiez Zannad, Brian Claggett, Finnian R. Mc Causland, João Pedro Ferreira, Akshay Desai, Ebrahim Barkoudah, John J.V. McMurray, Marc A. Pfeffer, Scott D. Solomon
Institutions: Brigham and Women's Hospital, Harvard University, Inserm, Centre Hospitalier Régional et Universitaire de Nancy, Défaillance Cardiovasculaire Aiguë et Chronique, Université de Lorraine, British Heart Foundation, University of Glasgow
Language: English
Field: Medicine
Open Access status: bronze
Funders: Boehringer Ingelheim, Abbott Laboratories, Amgen, Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Gilead Sciences, Takeda Pharmaceuticals U.S.A., Boston Scientific Corporation, Celladon Corporation, Jazz Pharmaceuticals, Ionis Pharmaceuticals, Cytokinetics, Bayer Fund, MyoKardia, Novo Nordisk, Servier, National Institutes of Health, Sanofi Pasteur, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases
OpenAlex ID: W3103053877
FWCI: 3.867
Cites: 26
Cited by: 46
Related to: 10